PRAME TCR Therapy Delivers Breakthrough in Uveal Melanoma

by Medscape • 2026/02/03 • 0 Comments

Dr Teresa Amaral reviews ESMO 2025 data showing unprecedented response rates with PRAME-directed TCR therapy in metastatic uveal melanoma.
Medscape Oncology

← OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in California

Omidenepag isopropyl may increase myopia in glaucoma →

Post navigation